Lisa Egerer

412 total citations
8 papers, 339 citations indexed

About

Lisa Egerer is a scholar working on Genetics, Infectious Diseases and Virology. According to data from OpenAlex, Lisa Egerer has authored 8 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 4 papers in Infectious Diseases and 4 papers in Virology. Recurrent topics in Lisa Egerer's work include Virus-based gene therapy research (6 papers), HIV Research and Treatment (4 papers) and RNA Interference and Gene Delivery (2 papers). Lisa Egerer is often cited by papers focused on Virus-based gene therapy research (6 papers), HIV Research and Treatment (4 papers) and RNA Interference and Gene Delivery (2 papers). Lisa Egerer collaborates with scholars based in Austria, Germany and United States. Lisa Egerer's co-authors include Dorotheé von Laer, Felix G. Hermann, Jens Bohne, Christel Baum, Tsanan Giroglou, Axel Schambach, Janine Kimpel, Alexander Muik, Guido Wollmann and Christian Marth and has published in prestigious journals such as Nature Communications, Journal of Virology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Lisa Egerer

8 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Egerer Austria 7 215 186 88 80 61 8 339
Jorn Kaspers Netherlands 8 264 1.2× 226 1.2× 133 1.5× 150 1.9× 30 0.5× 10 428
Linda J. Lockett Australia 11 256 1.2× 191 1.0× 107 1.2× 66 0.8× 25 0.4× 15 349
Maureen Boyd Australia 11 204 0.9× 352 1.9× 59 0.7× 74 0.9× 189 3.1× 12 454
Xiao‐Mei Rao United States 12 281 1.3× 294 1.6× 75 0.9× 149 1.9× 15 0.2× 24 473
Jerel Vega United States 7 100 0.5× 292 1.6× 105 1.2× 20 0.3× 38 0.6× 10 407
S Brown United States 7 236 1.1× 223 1.2× 125 1.4× 108 1.4× 30 0.5× 7 453
Beth Ann Antoni United States 8 197 0.9× 194 1.0× 121 1.4× 36 0.5× 136 2.2× 8 431
David Zuijdgeest Netherlands 5 179 0.8× 134 0.7× 116 1.3× 71 0.9× 15 0.2× 5 280
Yajin Ni United States 7 152 0.7× 182 1.0× 45 0.5× 60 0.8× 82 1.3× 10 289
Robert E. Throm United States 11 183 0.9× 199 1.1× 53 0.6× 184 2.3× 15 0.2× 21 485

Countries citing papers authored by Lisa Egerer

Since Specialization
Citations

This map shows the geographic impact of Lisa Egerer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Egerer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Egerer more than expected).

Fields of papers citing papers by Lisa Egerer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Egerer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Egerer. The network helps show where Lisa Egerer may publish in the future.

Co-authorship network of co-authors of Lisa Egerer

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Egerer. A scholar is included among the top collaborators of Lisa Egerer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Egerer. Lisa Egerer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Heilmann, Emmanuel, Janine Kimpel, Benedikt Hofer, et al.. (2021). Chemogenetic ON and OFF switches for RNA virus replication. Nature Communications. 12(1). 1362–1362. 7 indexed citations
2.
Wollmann, Guido, Lisa Egerer, Alexander Muik, et al.. (2016). Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. Molecular Therapy — Oncolytics. 3. 16021–16021. 72 indexed citations
3.
Egerer, Lisa, Hans‐Peter Kiem, & Dorotheé von Laer. (2015). C Peptides as Entry Inhibitors for Gene Therapy. Advances in experimental medicine and biology. 848. 191–209. 3 indexed citations
4.
Tober, Reinhard, Zoltán Bánki, Lisa Egerer, et al.. (2014). VSV-GP: a Potent Viral Vaccine Vector That Boosts the Immune Response upon Repeated Applications. Journal of Virology. 88(9). 4897–4907. 57 indexed citations
5.
Schmidt, Kerstin, Roland Zahn, Cornelia Richter, et al.. (2012). A Rationally Engineered Anti-HIV Peptide Fusion Inhibitor with Greatly Reduced Immunogenicity. Antimicrobial Agents and Chemotherapy. 57(2). 679–688. 28 indexed citations
6.
Egerer, Lisa, et al.. (2011). Secreted Antiviral Entry Inhibitory (SAVE) Peptides for Gene Therapy of HIV Infection. Molecular Therapy. 19(7). 1236–1244. 18 indexed citations
7.
Hermann, Felix G., et al.. (2009). Mutations in gp120 Contribute to the Resistance of Human Immunodeficiency Virus Type 1 to Membrane-Anchored C-Peptide maC46. Journal of Virology. 83(10). 4844–4853. 36 indexed citations
8.
Schambach, Axel, Jens Bohne, Christel Baum, et al.. (2005). Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression. Gene Therapy. 13(7). 641–645. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026